BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 19274369)

  • 1. HPV vaccination: the beginning of the end of cervical cancer? - A Review.
    Lepique AP; Rabachini T; Villa LL
    Mem Inst Oswaldo Cruz; 2009 Feb; 104(1):1-10. PubMed ID: 19274369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developments in L2-based human papillomavirus (HPV) vaccines.
    Schellenbacher C; Roden RBS; Kirnbauer R
    Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
    MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases.
    Cheng MA; Farmer E; Huang C; Lin J; Hung CF; Wu TC
    Hum Gene Ther; 2018 Sep; 29(9):971-996. PubMed ID: 29316817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human papillomavirus infection and the development of cervical cancer and related genital neoplasias.
    Paavonen J
    Int J Infect Dis; 2007 Nov; 11 Suppl 2():S3-9. PubMed ID: 18162244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human papillomavirus vaccine against cervical cancer: Opportunity and challenge.
    Wang R; Pan W; Jin L; Huang W; Li Y; Wu D; Gao C; Ma D; Liao S
    Cancer Lett; 2020 Feb; 471():88-102. PubMed ID: 31812696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prophylactic quadrivalent vaccine for the prevention of infection and disease related to HPV-6, -11, -16 and -18.
    Goldstone SE; Vuocolo S
    Expert Rev Vaccines; 2012 Apr; 11(4):395-406. PubMed ID: 22551023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using the new HPV vaccines in clinical practice.
    Widdice LE; Kahn JA
    Cleve Clin J Med; 2006 Oct; 73(10):929-35. PubMed ID: 17044318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HPV vaccination and cervical cancer.
    Szarewski A
    Curr Oncol Rep; 2012 Dec; 14(6):559-67. PubMed ID: 22890794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human papillomavirus: current status and issues of vaccination.
    Malik H; Khan FH; Ahsan H
    Arch Virol; 2014 Feb; 159(2):199-205. PubMed ID: 24022639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential impact of prophylactic human papillomavirus vaccination on oropharyngeal cancer.
    Guo T; Eisele DW; Fakhry C
    Cancer; 2016 Aug; 122(15):2313-23. PubMed ID: 27152637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Introducing human papillomavirus vaccines - questions remain.
    Paavonen J; Lehtinen M
    Ann Med; 2008; 40(3):162-6. PubMed ID: 18382882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent progress in vaccination against human papillomavirus-mediated cervical cancer.
    McKee SJ; Bergot AS; Leggatt GR
    Rev Med Virol; 2015 Mar; 25 Suppl 1():54-71. PubMed ID: 25752816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical trials of human papillomavirus vaccines and beyond.
    Lehtinen M; Dillner J
    Nat Rev Clin Oncol; 2013 Jul; 10(7):400-10. PubMed ID: 23736648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human papillomavirus infection: an old disease, a new vaccine.
    Giles M; Garland S
    Aust N Z J Obstet Gynaecol; 2006 Jun; 46(3):180-5. PubMed ID: 16704468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylactic HPV vaccines: reducing the burden of HPV-related diseases.
    Villa LL
    Vaccine; 2006 Mar; 24 Suppl 1():S23-8. PubMed ID: 16194583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The current state of therapeutic and T cell-based vaccines against human papillomaviruses.
    Yang A; Farmer E; Lin J; Wu TC; Hung CF
    Virus Res; 2017 Mar; 231():148-165. PubMed ID: 27932207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Human papillomavirus prophylactic vaccines: stakes and perspectives].
    Hantz S; Alain S; Denis F
    Gynecol Obstet Fertil; 2006; 34(7-8):647-55. PubMed ID: 16807045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.
    Muñoz N; Manalastas R; Pitisuttithum P; Tresukosol D; Monsonego J; Ault K; Clavel C; Luna J; Myers E; Hood S; Bautista O; Bryan J; Taddeo FJ; Esser MT; Vuocolo S; Haupt RM; Barr E; Saah A
    Lancet; 2009 Jun; 373(9679):1949-57. PubMed ID: 19493565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variation in genital human papillomavirus infection prevalence and vaccination coverage among men and women in the USA.
    Han JJ; Tarney CM; Song J
    Future Oncol; 2017 Jun; 13(13):1129-1132. PubMed ID: 28589730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.